Boehringer Ingelheim and Re-Vana Therapeutics Collaborate to Develop Long-Acting Ophthalmic Therapies

Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration and license agreement designed to accelerate the development of first-in-class extended-release therapies for vision-threatening eye diseases.

The collaboration combines Boehringer Ingelheim’s pipeline in eye health, which includes four clinical-stage assets, with Re-Vana’s delivery technology, which enables sustained release of therapeutics over 6 to 12 months. The companies say the collaboration will help reduce the need for frequent eye injections, a barrier to compliance and quality of life in patients with chronic ocular diseases.

Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana’s feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales.

For patients with retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), treatment often involves monthly injections directly into the eye. Re-Vana’s proprietary platform aims to deliver drugs over extended periods, potentially transforming how these conditions are managed.

“The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,” Michael O’Rourke, Re-Vana Chief Executive Officer, said in a company news release. “By combining our extended-release platform with Boehringer Ingelheim’s world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.”